Shared MRI fate unclear after Diagnostek sale

Article

Diagnostek of Albuquerque, NM, signed a definitive agreement lastmonth to be acquired by Medco Containment of Montvale, NJ. Medco'splans for Diagnostek's shared service MRI business are not clear,but the rationale for this merger was the complementarity

Diagnostek of Albuquerque, NM, signed a definitive agreement lastmonth to be acquired by Medco Containment of Montvale, NJ. Medco'splans for Diagnostek's shared service MRI business are not clear,but the rationale for this merger was the complementarity of thetwo firms' pharmacy lines. Diagnostek's imaging business doesnot appear to fit in as well to a merger of the two companies.

MRI services had become an increasingly small part of Diagnostek'srevenues over the past several years as it built up a large andprofitable mail-order pharmacy business (SCAN 2/28/90). The firmran a half dozen scanners, mostly high-field GE Signas and mostlyfor hospitals on a fee-per-scan basis.

Diagnostek had explored either selling its MRI systems or expandingfurther into the MRI center business and decided against bothoptions, according to Arthur C. Solomon, executive vice president.Solomon will continue with Medco as a senior executive followingthe merger.

High center prices, as well as the possibility of legislationrestricting referring-physician ownership more severely than currentfederal safe harbor guidelines, were factors mitigating againsta center buyout strategy.

"A year or so ago--because we have good financial resourcesand good (clinical) relationships--we looked at helping theselimited partnerships by coming in and doing buyouts," Solomontold SCAN. "We took a wait-and-see approach because of allthese states reacting with their own safe harbor provisions."

The 60/40 ownership guideline of the safe harbor regulationsallows for the maintenance of some physician participation. Withoutthis participation, the riskiness of most center deals is notworth the high multiples of earnings many physician owners areasking, he said.

Although Diagnostek has been approached by several potentialbuyers of its MRI business, no one offered a price high enoughto justify a sale, Solomon said. Potential buyers included sometrying to arrange rollups of multiple imaging facilities, he said.

"For the last two years we have had people calling uswanting to know what we want to do with (the MRI systems). Forus, the business has pretty much taken care of itself. They areprofitable. We have looked at the possibility of selling them,but no one came through with a deal we felt was more favorablethan holding on to them," Solomon said.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.